Cedars-Sinai Heart Institute, Los Angeles, CA 90048, USA.
Circ Arrhythm Electrophysiol. 2012 Feb;5(1):237-43. doi: 10.1161/CIRCEP.111.968057.
Sudden Cardiac Death (SCD) is responsible for an estimated 300,000 US deaths per year. Despite sophisticated resuscitation techniques and first responder systems, survival rates are very low. This is especially true for the majority of cases where the onset is unexpected and without prior cardiac symptoms; and further underscores the importance of finding better ways of early identification of subjects at risk of SCD. Although important contributions have been added from cohort studies as well as community-based studies, more pieces of the puzzle need to be solved. The use of plasma biomarkers is a common instrument for assessing cardiovascular risk in different subsets. In this review, we weigh the evidence regarding a potential role for plasma biomarkers in predicting SCD in the general population and suggest future investigative approaches that could be of clinical utility.
心源性猝死（SCD）每年导致约 30 万美国人死亡。尽管复苏技术和急救系统先进，但存活率非常低。对于大多数没有事先出现心脏症状且发病出乎意料的病例来说尤其如此；这进一步强调了寻找更好的方法来早期识别 SCD 高危人群的重要性。尽管队列研究和基于社区的研究都有重要贡献，但仍需要解决更多的问题。使用血浆生物标志物是评估不同亚组心血管风险的常用工具。在这篇综述中，我们权衡了血浆生物标志物在预测普通人群 SCD 方面的潜在作用的证据，并提出了未来可能具有临床应用价值的研究方法。
